Dr. Mark Schenerman is currently Professor of the Practice of Biotechnology and Graduate
Program Director at University of MD – Baltimore County and President of a consulting firm
(CMC Biotech-MAS Consulting) that he founded and is advising academic, industry, and
regulatory agency groups. Prior to this, he was Senior CMC Advisor for
Science/Technology/Strategy at Novavax. He is an experienced biopharmaceutical scientist and
executive who has most recently been responsible for developing and aligning crossfunctionally
Chemistry, Manufacturing, & Control (CMC) strategy leading to global regulatory
filings (IND through BLA) at MedImmune/AstraZeneca. Dr. Schenerman was also responsible
for maintaining and building key collaborations externally with peer biopharmaceutical
companies, academic institutions, and government agencies to advance regulatory science.
Prior to this, Dr. Schenerman headed an R&D group that performed physicochemical and
biological characterization of preclinical and clinical products, stability and release testing,
technology transfer to quality control and ongoing product development support. Since joining
MedImmune in 1994, Dr. Schenerman played an integral role in developing and leading the
company’s Analytical Biochemistry function, supporting all stages of product development.
Prior to joining MedImmune, Dr. Schenerman held positions in biologics development and
research and development at Bristol-Myers Squibb Company and was a post-doctoral associate
at Cornell University. He earned his Bachelor’s degree in Medical Technology at the University
of Maryland and his doctorate in Biochemistry and Molecular Biology at the University of
Florida.